Craig

Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study

Jennifer A. Smith, G. Acton, H. Kantarjian, 2015 .